MUMBAI, India, June 19 -- Intellectual Property India has published a patent application (202617057649 A) filed by Ligachem Biosciences Inc. on May 06, 2026, for Anti-Claudin 18.2 Antibody Drug Conjugates Comprising Topoisomerase I Inhibitor And Uses Thereof.
Inventors include Jang, Tae Ik; Park, Chang Sik; Baek, Eun Ji; Song, Ho Young; Chae, Sang Eun; Park, Se Yeon; and Chung, Chul-Woong.
The application for the patent was published on June 05, 2026, under issue no. 23/2026.
Abstract: The present disclosure relates to an antibody-drug conjugate (ADC) targeting human Claudin 18 isoform 2 (CLDN 18.2) and use thereof, and more particularly, to an ADC including an antibody or antigen-binding fragment thereof that binds to human CLDN18.2, and a topoisomerase I inhibitor (e.g., a camptothecin); and use of ADCs for the treatment and/or treatment of diseases, more particularly, hyperproliferative and/or angiogenic diseases, such as cancer diseases.
Disclaimer: Curated by HT Syndication.
